New Study Highlights Heart Risks to Taking GlaxoSmithKline's Avandia
A new study has found that long-term use of Type 2 diabetes drug Avandia
increases heart attack risk by more than 40 percent and doubles the chance of
heart failure.
The new analysis, by researchers from Wake Forest
University Baptist Medical Center and published in the September 12 issue of the
Journal of the American Medical Association, is one of the first to
evaluate how long-term use of Avandia affects risk of heart attacks, heart
failure and mortality.
The four studies involved followed more than
14,000 patients for at least a year.
Researchers found that long-term use
of GlaxoSmithKline's Avandia (known generically as rosiglitazone) increased the
risk of heart attack by 42 percent and doubled the risk of heart
failure.
Lead author on the study, Sonal Singh M.D., estimated that 3.5
million patients in the U.S. take Avandia for diabetes. In a Wake Forest press
release, Singh said the study’s findings suggest that Avandia “may cause more
than 4,000 excess heart attacks and 9,000 excess cases of heart failure a year.”
The press release went on to say that researchers estimate that for
every 220 diabetic patients treated with Avandia for one year, one will have a
heart attack linked to the drug. And, there would be one case of heart failure
for every 30 people taking the drug for one year.
If you or a loved one
has suffered cardiac complications after ingesting Avandia, you deserve the
guidance of a knowledgeable drug attorney. Get a free case review by filling out
the form below.
see also:
Arkansas Lawsuit
Arkansas Lawsuit: Avandia (Rosiglitazone) Caused My Heart ProblemsArkansas Lawsuit Filed; heart woes blamed on Avandia (rosiglitazone)
Warning Letter, 2001
Read the Warning Letter from 2001 on Avandia (Generic Rotiglitazone)Warning Sent to Glaxo Years Ago on Avandia (generic Rotiglitazone)
News & Warnings
Avandia Breaking News: Glaxo Warned in 2001 about Misleading MarketingBloomberg News: FDA Warned Glaxo about Avandia Marketing in 2001


